FDA approved Yescarta CAR-T for relapsed or refractory large B-cell lymphoma
Dated 18 October 2017: FDA approved Yescarta CAR-T for relapsed or refractory large B-cell lymphoma. In the causal graph this event strengthens the driver Biotechnology Innovation.
Who was responsible
Contribution type and responsibility level for each recorded actor — not sole-author shorthand.
No public contributors are listed for this fact.
What changed
Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.
- FactFDA approved Yescarta CAR-T for relapsed or refractory large B-cell lymphoma
- strengthensDriverBiotechnology Innovation
provisional weight · verified
Causal path
How this event connects to drivers and indicators in the graph.
- FactFDA approved Yescarta CAR-T for relapsed or refractory large B-cell lymphoma
- strengthensDriverBiotechnology Innovation
Cite this page
Factrail. (2026). FDA approved Yescarta CAR-T for relapsed or refractory large B-cell lymphoma. Factrail. https://factrail.ai/facts/fda-yescarta-car-t-lymphoma-approval-2017
https://factrail.ai/facts/fda-yescarta-car-t-lymphoma-approval-2017
Accessed 15 October 2026.
By the Factrail desk · Method: how we source and score · Last reviewed
Dispute this factNamed here, or represent someone who is? Request a right of reply.